Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-596

First 596 Last

Share
Profile

Follow
Uboy

4,680 Posts.

1083

16/10/19

16:12

Post #: 40913747
Share

Originally posted by Uboy ↑

DMD market opportunities are being recognised by top US Hedge Funds.......ANP will be received well when Diamond and Goolsbee do the roadshow.

Sarepta's PR work will pay-off for ANP too

Take a look at the top US Hedge Funds that have positions in Sarepta.

Hedge Funds Have Never Been This Bullish On Sarepta Therapeutics Inc (SRPT)

Reymerlyn Martin
Insider Monkey•October 13, 2019
….

Heading into the third quarter of 2019, a total of 48 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 9% from the first quarter of 2019. On the other hand, there were a total of 47 hedge funds with a bullish position in SRPT a year ago. So, let's check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

[BCOLOR=rgba(0, 0, 0, 0.5)]View photos[/BCOLOR]
SRPT_oct2019
More

Among these funds, venBio Select Advisor held the most valuable stake in Sarepta Therapeutics Inc (NASDAQ:SRPT), which was worth $212.7 million at the end of the second quarter. On the second spot was Adage Capital Management which amassed $182.3 million worth of shares. Moreover, OrbiMed Advisors, Cadian Capital, and Partner Fund Management were also bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT), allocating a large percentage of their portfolios to this stock.
Now, key hedge funds have jumped into Sarepta Therapeutics Inc (NASDAQ:SRPT) headfirst. Partner Fund Management, managed by Christopher James, created the largest position in Sarepta Therapeutics Inc (NASDAQ:SRPT). Partner Fund Management had $83.1 million invested in the company at the end of the quarter. Jeremy Green's Redmile Group also initiated a $62.6 million position during the quarter. The other funds with new positions in the stock are Ken Greenberg and David Kim's Ghost Tree Capital, Thomas E. Claugus's GMT Capital, and Renaissance Technologies.
.

Expand

venBio Select Advisor holds $212.7 million of Sarepta stock.

Adage Capital Management holds $182.3 million

These elephants have deep knowledge of the challenges Sarepta faces re FDA efficacy queries.

They have large positions in Sarepta they need to protect.

No doubt Goolsbee will be key player going forward as the ANP story unfolds.

.

Last edited by Uboy: 16/10/19

ANP Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
21 Upvote

0 Great analysis

Reply